It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...

For many people with early breast cancer (eBC), remission doesn’t mean everything goes back to normal. There are scars from ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug in combination with atezolizumab and bevacizumab in patients with unresectable, ...

"According to the World Health Organization, about one third of cancers can be prevented through measures like proper ...

Liam Handley - who had suffered from anxiety for much of his life - went to his GP with chest pains, which his doctor put ...

Dr Mayowa Kolade, a consultant nuclear medicine specialist at the University College Hospital, Ibadan, in this interview with ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today ...

The Loose Women presenter, 59, made the candid confession during a discussion about visiting family members' final resting places.